ReviewHuman vaccines & immunotherapeutics2015
Strategy vaccination against Hepatitis B in China.
Review in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 51 citations in OpenAlex.
- Spatiotemporal epidemiology of hepatitis B in Central China: urbanization drivers and implications for adult-targeted control strategies.BMC public health · 2026Article
- Spatio-temporal clustering characteristics of hepatitis B in China: an 18-year study.Scientific reports · 2026Article
- HBV biomarkers outperform host genetic variants in distinguishing occult HBV infection from chronic carriers.iScience · 2026Article
- Lipid Nanoparticle-Encapsulated PolyI:C as an Adjuvant Enhances Both Humoral and Cellular Immune Responses to the Hepatitis B Vaccine.Vaccines · 2026Article
- Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications.Portal hypertension & cirrhosis · 2026Review
- A Community-Engaged Approach to Identifying and Addressing Viral Hepatitis Determinants in Michigan Asian American Communities.Journal of viral hepatitis · 2026Article
- Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B.Viruses · 2025Review
- Cost-Effectiveness of Universal Screen-and-Treat Strategies for Reducing Morbidity and Mortality of Chronic Hepatitis B in a High-Endemicity City.Journal of viral hepatitis · 2025Article
- Liver cirrhosis in 2021: Global Burden of Disease study.PloS one · 2025Article
- Barriers and facilitators of prevention of infections related to cancer: A systematic literature review.Heliyon · 2024Article
- The History of Controlling and Treating Infectious Diseases in Ancient China.Current medical science · 2024Review
- Evaluating the impact of COVID-19 outbreak on hepatitis B and forecasting the epidemiological trend in mainland China: a causal analysis.BMC public health · 2024Article
- Enhanced Cellular Immunity for Hepatitis B Virus Vaccine: A Novel Polyinosinic-Polycytidylic Acid-Incorporated Adjuvant Leveraging Cytoplasmic Retinoic Acid-Inducible Gene-Like Receptor Activation and Increased Antigen Uptake.Biomaterials research · 2024Article
- Epidemiological and clinical profile of pediatric hepatitis B virus infections in Wuhan: a retrospective cohort study.BMC pediatrics · 2023Article
- Potentiating humoral and cellular immunity using a novel hybrid polymer-lipid nanoparticle adjuvant for HBsAg-VLP vaccine.Journal of nanobiotechnology · 2023Article
- Trends in sexually transmitted and blood-borne infections in China from 2005 to 2021: a joinpoint regression model.BMC infectious diseases · 2023Article
- Potentiating the Immune Responses of HBsAg-VLP Vaccine Using a Polyphosphoester-Based Cationic Polymer Adjuvant.ACS applied materials & interfaces · 2023Article
- Hepatitis B immunization status and risk factors of people aged 1 to 69 in Huangpu District, Shanghai, China.Frontiers in public health · 2023Article
- Association of vaccine policy with virus infection and awareness of hepatitis B in Fujian, China.Human vaccines & immunotherapeutics · 2022Article
- Association between vaccine dose and risk of hepatitis B virus infection in Fujian Province, China.Human vaccines & immunotherapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B (HB) is a serious public health problem in China. Up to now, the hepatitis B virus (HBV) vaccination was the most cost-effective way to prevent HBV infection. Since 1992, when the Chinese government prioritized implementing the HBV vaccinations for newborns, China began to see a larger reduction in HBV infections. For children under 5 years, the prevalence of hepatitis B surface antigen (HBsAg) has decreased to 1.0%. However, many additional challenges for the prevention and control of HBV infection in China remain. There is a lack of knowledge of the significant impact of the HBV vaccination for the general public with 93 million HBV carriers and chronic HBV patients as infection sources. Therefore, the HBV vaccine application should focus on the optimization of immunization strategies according to HBV prevalence characteristics, improve the public's knowledge of HBV vaccinations, and help to ensure the protective effects of the HBV vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.